Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 4/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.33 |
| ▸ | MAP3K12 | Q12852 | 2/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | LPL | P06858 | 2/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.30 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.30 |
| ▸ | ACACB | O00763 | 2/20 | 0.30 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29197236 | 1.00 | USP30 (0.36) | USP30AOC3DYRK1AMAP3K12PDE10A | |
| SCHEMBL24894892 | 1.00 | USP30 (0.36) | USP30AOC3DYRK1AMAP3K12PDE10A | |
| SCHEMBL24894999 | 0.93 | LRRK2 (0.35) | USP30AOC3MAP3K12PDE10AFFAR1 | |
| SCHEMBL29197145 | 0.93 | LRRK2 (0.35) | USP30AOC3MAP3K12PDE10AFFAR1 | |
| SCHEMBL31153309 | 0.93 | LRRK2 (0.35) | USP30AOC3MAP3K12PDE10AFFAR1 | |
| SCHEMBL24894860 | 0.92 | USP30 (0.35) | USP30AOC3MAP3K12FFAR1LPL | |
| SCHEMBL30018560 | 0.83 | TSHR (0.37) | USP30FFAR1LPLLIPG | |
| SCHEMBL30975295 | 0.83 | USP30 (0.40) | USP30LPLLIPGDGAT1 | |
| SCHEMBL1840795 | 0.82 | SMO (0.38) | USP30AOC3FFAR1LPLLIPG | |
| SCHEMBL30018701 | 0.81 | ADRA1A (0.37) | USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240336627-A1 | NOVEL COMPOUNDS FOR THE DIAGNOSIS OF TDP-43 PROTEINOPATHIES | AC IMMUNE SA (CH) | 2024-10-10 | — | — | US | disclosed |
| US-20210252175-A1 | NOVEL COMPOUNDS FOR DIAGNOSIS | AC IMMUNE SA (CH) | 2021-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210252175-A1 | NOVEL COMPOUNDS FOR DIAGNOSIS | SNCA, PARK7, NLN | USP30 2555/4885AOC3 1065/4885DYRK1A 2694/4885 |
| US-20240336627-A1 | NOVEL COMPOUNDS FOR THE DIAGNOSIS OF TDP-43 PROTEINOPATHIES | TARDBP, FUS, MAPT | USP30 1100/4885AOC3 2324/4885DYRK1A 4177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.